BioPlus Co Ltd
KOSDAQ:099430
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (8.3), the stock would be worth ₩9 666.07 (66% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5 | ₩5 840 |
0%
|
| 3-Year Average | 8.3 | ₩9 666.07 |
+66%
|
| 5-Year Average | 8.9 | ₩10 439.87 |
+79%
|
| Industry Average | 5.7 | ₩6 671.9 |
+14%
|
| Country Average | 5.4 | ₩6 336.21 |
+8%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
359.4B KRW | 5 | 22.4 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY | 11.7 | 39.1 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
59.4B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.9B CHF | 6.7 | 37.2 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
93.1B DKK | 5.9 | 23.1 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.2B USD | 4.4 | 32.1 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.3B GBP | 5.1 | 32.5 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 3.4 | -15.6 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.8B CNY | 14 | 22.2 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
879B JPY | 9.2 | 49.7 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.3B CNY | 11.3 | 22.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 2.7 |
| Median | 5.4 |
| 70th Percentile | 10.1 |
| Max | 19 609.2 |
Other Multiples
BioPlus Co Ltd
Glance View
BioPlus Co., Ltd. is engaged in the manufacturing and supplying of diverse dermal fillers. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-09-27. The firm is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.
